Targeting EGFR and PI3K pathways in ovarian cancer

British Journal of Cancer

Volumn 109, Issue 7, 2013, Pages 1786-1794

  Glaysher, S ^a   Bolton, L M ^a   Johnson, P ^a   Atkey, N ^b   Dyson, M ^b   Torrance, C ^c   Cree, I A ^d  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c Molecular Biotechnology Center   (United Kingdom)

^d UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

erlotinib; gefinitib; MTOR; ovarian cancer; sirolimus; ZSTK474

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IC 50; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIROLIMUS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 84885182699     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.529     Document Type: Article

References (27)

1. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M et al. (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55(22): 5276-5278.
2. Bartlett JM, Starczynski J, Atkey N, Kay E, O'Grady A, Gandy M, Ibrahim M, Jasani B, Ellis IO, Pinder SE, Walker RA (2011) HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 64(8): 649-653.
3. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G (2008) Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98(5): 923-930.
4. Blank SV, Chang R, Muggia F (2005) Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer. Oncology (Williston Park) 19(4): 553-559.
5. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21): 7678-7681.
6. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL (2012) Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad SciUSA 109: 2718-2723.
7. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
8. Glaysher S, Cree IA (2011) Cell sensitivity assays: the ATP-based tumor chemosensitivity assay. Methods Mol Biol 731: 247-257.
9. Glaysher S, Gabriel FG, Cree IA (2011) Measuring gene expression from cell cultures by quantitative reverse-transcriptase polymerase chain reaction. Methods Mol Biol 731: 381-393.
10. Glaysher S, Gabriel FG, Johnson P, Polak M, Knight LA, Parker K, Poole M, Narayanan A, Cree IA (2010) Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer 103(5): 656-662.
11. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47(2): 331-385.
12. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118(7): 2609-2619.
13. Hamburger AW (2001) Detection of ErbB receptor family tyrosyl phosphorylation in ovarian carcinoma cells. Methods Mol Med 39: 571-575.
14. Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA, Coukos G, Weber BL, Degenhardt Y (2011) Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 50(8): 606-618.
15. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus DB (2010) HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 70(5): 1989-1999.
16. Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI (2006) Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 13(Suppl 1): S45-S51.
17. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA (2004) The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 4: 83.
18. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, Timorek A, Dansonka-Mieszkowska A, Kupryjanczyk J (2009) PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 8(1): 21-26.
19. Larsen AK, Ouaret D, El Ouadrani K, Petitprez A (2011) Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 131(1): 80-90.
20. Mayr D, Kanitz V, Amann G, Engel J, Burges A, Lohrs U, Diebold J (2006) HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 48(2): 149-156.
21. Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27(13): 2278-2287.
22. Murphy M, Stordal B (2011) Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat 14(3): 177-190.
23. Niikura H, Sasano H, Sato S, Yajima A (1997) Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 16(1): 60-68.
24. Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B, Wan Y (2005) Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol 27(5): 1441-1448.
25. Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, Workman P, Jackman AL (2006) Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 5(5): 1197-1208.
26. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27(28): 3944-3956.
27. Yang L, Li J, Ran L, Pan F, Zhao X, Ding Z, Chen Y, Peng Q, Liang H (2011) Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells. J Gastrointest Surg 15(6): 942-957.